FOOD EFFECT STUDY OF THE INVESTIGATIONAL AURORA A KINASE (AAK) INHIBITOR MLN8237 (ALISERTIB) IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Falchook, G. S. [1 ]
Zhou, X. [2 ]
Rosen, L. S. [3 ]
Venkatakrishnan, K. [2 ]
Kurzrock, R. [1 ]
Mahalingam, D. [4 ]
Goldman, J. [5 ]
Jung, J. [6 ]
Milch, C. [2 ]
Sarantopoulos, J. [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Millennium Pharmaceut Inc, Clin Pharmacol, Cambridge, MA USA
[3] Premiere Oncol, Oncol, Santa Monica, CA USA
[4] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX 78229 USA
[5] UCLA Med Ctr, David Geffen Sch Med, Div Hematol Oncol, Santa Monica, CA USA
[6] Millennium Pharmaceut Inc, Biostat, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：168 / 168
页数：1
相关论文
共 50 条
  • [31] Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors
    Semrad, Thomas J.
    Kim, Edward J.
    Gong, I-Yeh
    Li, Tianhong
    Christensen, Scott
    Arora, Mili
    Riess, Jonathan W.
    Gandara, David R.
    Kelly, Karen
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (02) : 335 - 341
  • [32] PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EXPOSURE-PD RELATIONSHIPS OF THE INVESTIGATIONAL DRUG MLN8237, AN AURORA A KINASE INHIBITOR IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Zhou, X.
    Ecsedy, J.
    Danaee, H.
    Fingert, H.
    Venkatakrishnan, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S67 - S67
  • [33] Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors
    Thomas J. Semrad
    Edward J. Kim
    I-Yeh Gong
    Tianhong Li
    Scott Christensen
    Mili Arora
    Jonathan W. Riess
    David R. Gandara
    Karen Kelly
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 335 - 341
  • [34] MLN8237 (ALISERTIB), A SELECTIVE AURORA A KINASE (AAK) INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC): PHASE 2 RESULTS
    Havel, Libor
    Dees, Claire
    Lockhart, Craig
    Bennouna, Jaafar
    Serwatowski, Piotr
    Liu, Stephen
    Niu, Huifeng
    Badola, Sunita
    Schusterbauer, Claudia
    Ullmann, Claudio Dansky
    Zhang, Bin
    Benaim, Ely
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S221 - S222
  • [35] A phase 1b study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors
    Davis, S. Lindsey
    Lam, Elaine T.
    Corr, Bradley R.
    O'Bryant, Cindy L.
    Glode, Ashley
    Adler, Nichole
    Pitts, Todd M.
    Tentler, John J.
    Capasso, Anna
    Dailey, Kyrie
    Serkova, Natalie J.
    Weekes, Colin D.
    Gustafson, Daniel L.
    Lieu, Christopher H.
    Messersmith, Wells A.
    Leong, Stephen
    Eckhardt, S. Gail
    Diamond, Jennifer R.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [36] A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma
    Rosenthal, Allison
    Kumar, Shaji
    Hofmeister, Craig
    Laubach, Jacob
    Vij, Ravi
    Dueck, Amylou
    Gano, Katherine
    Stewart, A. Keith
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (02) : 323 - 325
  • [37] A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase a, in Myelofibrosis
    Gangat, Naseema
    Swords, Ronan T.
    Stein, Brady Lee
    Marinaccio, Christian
    Watts, Justin M.
    Frankfurt, Olga
    Altman, Jessica K.
    Al-Kali, Aref
    Zblewski, Darci
    Gurbuxani, Sandeep
    Wen, Jeremy Q.
    Tapia, Roberto
    Barath, Stephanie
    Graf, Amy
    Handlogten, Amy
    Dinh, Yvonne Trang
    Englund, Kristen
    Patel, Shradha
    Bodes, Orlando
    Ogden, Jillian
    Giles, Francis J.
    Tefferi, Ayalew
    Crispino, John D.
    BLOOD, 2017, 130
  • [38] Translational Exposure-Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)
    Huck, Jessica J.
    Zhang, Mengkun
    Mettetal, Jerome
    Chakravarty, Arijit
    Venkatakrishnan, Karthik
    Zhou, Xiaofei
    Kleinfield, Rob
    Hyer, Marc L.
    Kannan, Karuppiah
    Shinde, Vaishali
    Dorner, Andy
    Manfredi, Mark G.
    Shyu, Wen Chyi
    Ecsedy, Jeffrey A.
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (09) : 2170 - 2183
  • [39] Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies
    Siddiqi, Tanya
    Frankel, Paul
    Beumer, Jan H.
    Kiesel, Brian F.
    Christner, Susan
    Ruel, Chris
    Song, Joo Y.
    Chen, Robert
    Kelly, Kevin R.
    Ailawadhi, Sikander
    Kaesberg, Paul
    Popplewell, Leslie
    Puverel, Sandrine
    Piekarz, Richard
    Forman, Stephen J.
    Newman, Edward M.
    LEUKEMIA & LYMPHOMA, 2020, 61 (02) : 309 - 317
  • [40] A phase Ib study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors, expansion cohort data
    Davis, S. L.
    Leong, S.
    Messersmith, W.
    Purcell, T.
    Lam, E.
    Corr, B.
    Leal, A.
    O'bryant, C.
    Glode, A.
    Adler, N.
    Serkova, N.
    Diamond, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E142 - E142
12345